For cost-effective, streamlined, targeted next-generation sequencing (NGS) of specific genetic diseases or conditions, Illumina offers TruSight sequencing panels. Designed with recognized healthcare experts at leading institutions, TruSight panels comprise oligo probes targeting genes and regions thought to be relevant for particular diseases or conditions.
Each TruSight sequencing panel offers:
Solutions to enable comprehensive genomic profiling, from tissue to liquid biopsy samples.
Assays designed to identify relevant biomarkers in guidelines and clinical research, such as tumor mutational burden (TMB) and microsatellite instability (MSI).
Comprehensive panel detects single-nucleotide variants (SNVs), amplifications, and fusions that contribute to solid tumor progression.
Targeting 507 fusion associated genes in cancer; detects known and novel fusion gene partners.
Targeting 1385 oncology genes for gene expression, variant and fusion detection in all RNA sample types including FFPE.
Uses expert-defined content to identify somatic mutations in myeloid malignancies.
Expert-defined content targeting 113 genes associated with genetic cancer risk predisposition.
Sequencing research panels targeting 94 genes and 284 SNPs associated with a predisposition towards various cancers.
Focused panel that assesses common somatic variants in solid tumors.
Comprehensive panels targeting disease-associated regions of the exome with high analytical sensitivity and specificity.
A comprehensive, cost-effective solution for identifying causal variants implicated in inherited cardiac conditions.